🇺🇸 Saccharomyces boulardii in United States

388 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 81 reports (20.88%)
  2. Pyrexia — 42 reports (10.82%)
  3. Nausea — 38 reports (9.79%)
  4. Fatigue — 36 reports (9.28%)
  5. Fall — 35 reports (9.02%)
  6. Weight Decreased — 33 reports (8.51%)
  7. Dyspnoea — 32 reports (8.25%)
  8. Dehydration — 31 reports (7.99%)
  9. Pneumonia — 31 reports (7.99%)
  10. Asthenia — 29 reports (7.47%)

Source database →

Saccharomyces boulardii in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Saccharomyces boulardii approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Saccharomyces boulardii in United States?

RESnTEC, Institute of Research is the originator. The local marketing authorisation holder may differ — check the official source linked above.